Allogenic bone marrow transplantation in multiple myeloma

Article Abstract:

Multiple myeloma results from the tumor-like growth of bone marrow cells. At present, the condition is generally fatal. However, there are indications that chemotherapy may be effective if greater doses and more aggressive drug combinations are used. However, the doses of chemotherapeutic agents that can be used are limited by destruction of normal bone marrow cells, a dangerous side effect. One method of circumventing this problem is to use a dose of drugs that virtually ablates the bone marrow, followed by bone marrow transplantation from a closely matched donor. This method has now been used to treat 90 patients with multiple myeloma. After a follow-up period of 79 months, 47 patients were still alive, and the remainder had died. Ten patients died soon after the bone marrow transplantation. Of the remaining patients, 37 had no signs of graft-versus-host disease (GVHD), in which the bone marrow of the donor attacks the tissues of its new host. Twenty-two patients had grade I GVHD, 10 had grade II, four had grade III, and four had grade IV GVHD. Patients with grade I GVHD or without GVHD were more likely to survive than patients with more extensive GVHD. Achieving a complete remission after bone marrow transplantation was also a significant predictor of long-term survival. The results of this study indicate that bone marrow transplantation from a carefully matched sibling may be an important treatment for some patients with multiple myeloma. (Consumer Summary produced by Reliance Medical Information, Inc.)

Bone marrow, Bone marrow transplantation

---

Single versus double autologous stem-cell transplantation for multiple myeloma

Article Abstract:

Patients with multiple myeloma may benefit from receiving two autologous stem-cell transplants instead of one, according to a study of 399 patients. Patients who received two stem cell transplants had better outcomes and lived longer than those who received one stem cell transplant. An autologous transplant means the patient donated his or her own cells to be used in the transplant.

Evaluation, Hematopoietic stem cells, Hematopoietic stem cell transplantation

---

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

Article Abstract:

Granulocyte colony-stimulating factor (G-CSF) may make cancer cells in patients with acute myeloid leukemia more sensitive to chemotherapy, according to a study of 640 patients. A greater percentage of patients who received G-CSF were alive four years after the treatment compared to those who did not receive G-CSF. G-CSF did not benefit patients with a poor prognosis.

Patient outcomes, Prognosis, Drug therapy, Granulocyte colony-stimulating factor, Acute myelocytic leukemia

Similar abstracts:

• Abstracts: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
• Abstracts: Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission
• Abstracts: Bowen's disease and internal cancer. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing
• Abstracts: The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections
• Abstracts: DNA content flow cytometry as a prognostic factor for node-positive breast cancer: the role of multiparameter ploidy analysis and specimen sonication

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.